Your browser doesn't support javascript.
loading
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area
Dianna Ng; Gregory Goldgof; Brian Shy; Andrew Levine; Joanna Balcerek; Sagar P Bapat; John Prostko; Mary Rodgers; Kelly Coller; Sandra Pearce; Sergej Franz; Li Du; Mars Stone; Satish Pillai; Alicia Sotomayor-Gonzalez; Venice Servellita; Claudia Sanchez-San Martin; Andrea Granados; Dustin R Glasner; Lucy M Han; Kent Truong; Naomi Akagi; David N Nguyen; Neil Neumann; Daniel Qazi; Elaine Hsu; Wei Gu; Yale A Santos; Brian Custer; Valerie Green; Phillip Williamson; Nancy K Hills; Chuanyi M Lu; Jeffrey D. Whitman; Susan Stramer; Candace Wang; Kevin Reyes; Jill Hakim; Kirk Sujishi; Fariba Alazzeh; Lori Pharm; Ching-Ying Oon; Steve Miller; Theodore Kurtz; John Hackett Jr.; Graham Simmons; Michael P Busch; Charles Y Chiu.
Afiliación
  • Dianna Ng; University of California, San Francisco
  • Gregory Goldgof; University of California, San Francisco
  • Brian Shy; University of California, San Francisco
  • Andrew Levine; University of California, San Francisco
  • Joanna Balcerek; University of California, San Francisco
  • Sagar P Bapat; University of California, San Francisco
  • John Prostko; Abbott Laboratories
  • Mary Rodgers; Abbott Laboratories
  • Kelly Coller; Abbott Laboratories
  • Sandra Pearce; Abbott Laboratories
  • Sergej Franz; Vitalant Research Institute
  • Li Du; University of California, San Francisco
  • Mars Stone; Vitalant Research Institute
  • Satish Pillai; Vitalant Research Institute
  • Alicia Sotomayor-Gonzalez; University of California, San Francisco
  • Venice Servellita; University of California, San Francisco
  • Claudia Sanchez-San Martin; University of California, San Francisco
  • Andrea Granados; University of California, San Francisco
  • Dustin R Glasner; University of California, San Francisco
  • Lucy M Han; University of California, San Francisco
  • Kent Truong; University of California, San Francisco
  • Naomi Akagi; University of California, San Francisco
  • David N Nguyen; University of California, San Francisco
  • Neil Neumann; University of California, San Francisco
  • Daniel Qazi; University of California, San Francisco
  • Elaine Hsu; University of California, San Francisco
  • Wei Gu; University of California, San Francisco
  • Yale A Santos; University of California, San Francisco
  • Brian Custer; Vitalant Research Institute
  • Valerie Green; Creative Testing Solutions
  • Phillip Williamson; Creative Testing Solutions
  • Nancy K Hills; University of California, San Francisco
  • Chuanyi M Lu; University of California, San Francisco
  • Jeffrey D. Whitman; University of California, San Francisco
  • Susan Stramer; American Red Cross
  • Candace Wang; University of California, San Francisco
  • Kevin Reyes; University of California, San Francisco
  • Jill Hakim; University of California, San Francisco
  • Kirk Sujishi; University of California, San Francisco
  • Fariba Alazzeh; University of California, San Francisco
  • Lori Pharm; University of California, San Francisco
  • Ching-Ying Oon; University of California, San Francisco
  • Steve Miller; University of California, San Francisco
  • Theodore Kurtz; University of California, San Francisco
  • John Hackett Jr.; Abbott Laboratories
  • Graham Simmons; Vitalant Research Institute
  • Michael P Busch; Vitalant Research Institute
  • Charles Y Chiu; University of California, San Francisco
Preprint en Inglés | medRxiv | ID: ppmedrxiv-20107482
ABSTRACT
We report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seropositivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors. We additionally describe the longitudinal dynamics of immunoglobulin-G, immunoglobulin-M, and in vitro neutralizing antibody titers in COVID-19 patients. Neutralizing antibodies rise in tandem with immunoglobulin levels following symptom onset, exhibiting median time to seroconversion within one day of each other, and there is >93% positive percent agreement between detection of immunoglobulin-G and neutralizing titers.
Licencia
cc_by_nc_nd
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Estudio observacional / Estudio pronóstico Idioma: Inglés Año: 2020 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Estudio observacional / Estudio pronóstico Idioma: Inglés Año: 2020 Tipo del documento: Preprint